D&D Pharmatech has been developing innovative peptide-based therapies for chronic diseases with high unmet medical needs, such as metabolic diseases like obesity, MASH (Metabolic Dysfunction-Associated Steatohepatitis), and diabetes, as well as fibrotic diseases. This collaboration with LG AI Research Institute is expected to accelerate these efforts.

AI-based Oral Peptide New Drug Development

This collaboration between D&D Pharmatech and LG AI Research Institute has the potential to change the paradigm of new drug development. LG AI Research Institute utilizes AI models that analyze the structure of disease-causing substances to design optimal peptide sequences and discover new drug candidates. D&D Pharmatech is responsible for the structural design, synthesis, and evaluation of AI-derived candidates, as well as preclinical and clinical trials, and global regulatory approvals.

• Introduction of a Circular Learning Structure: After D&D Pharmatech verifies the candidate substances designed by LG AI Research Institute, the results are reflected back into the AI model to continuously enhance its performance.
• Focus on Oral Peptides: Existing peptide drugs were easily broken down by gastrointestinal digestive enzymes, limiting their development to injectables. Both companies aim to complete oral therapies in pill form by innovating safety and absorption rates with AI technology.
• Key Technology ‘ORALINK’: D&D Pharmatech possesses ‘ORALINK,’ a core platform technology that enhances the in-vivo absorption rate of oral peptide drugs.

Key Pipelines and Technology Export Status

D&D Pharmatech is building promising pipelines in various disease areas, attracting attention from the global market. In particular, DD01, a MASH treatment candidate, has shown statistically significant results in Phase 2 biopsy results, raising expectations for technology transfer. DD01 showed positive results, including improved liver fibrosis, at week 12 of the planned 48-week clinical trial.

• Oral Obesity Treatment: In 2023, D&D Pharmatech licensed out oral obesity treatment candidates DD02S, DD03, MET06, and others to the US biotech company Metsera. Subsequently, additional substances, including the GLP-1/GIP dual agonist DD14, were included, expanding the contract size to over approximately $800 million.
• Neurodegenerative Disease Treatment NLY01: NLY01, a candidate for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, works by inhibiting neuroinflammation to protect brain nerve cells and is awaiting Phase 2 clinical trials for multiple sclerosis.
• GLP-1 Agonists: The company possesses various GLP-1-based candidate substances for diabetes and obesity treatment and is preparing for clinical trials of oral long-acting GLP-1 target substances such as MET-224o and MET-097o.

Securing Continuous Growth Engines

D&D Pharmatech is steadily building its foundation for innovative new drug development. After listing on KOSDAQ in May 2024, the company successfully completed the issuance of 226.5 billion won worth of convertible bonds (CB) in May 2026. These funds will be used to accelerate the clinical development of key pipelines, including the fibrosis treatment TLY012. Furthermore, the potential for collaboration with global pharmaceutical companies and expectations for technology exports are major factors stimulating investment sentiment.

The company aims to provide new hope to patients with difficult-to-treat diseases and create a healthy future through continuous global clinical development and various partnerships. A review of D&D Pharmatech’s pipeline overview reveals active research and development in various fields, including obesity, neurodegenerative diseases, and fibrotic diseases.

D&D Pharmatech is expected to lead the era of AI new drug development through its collaboration with LG AI Research Institute and open new horizons for oral peptide new drugs. The success of clinical trials for key pipelines and news of technology exports will continue to be core drivers of D&D Pharmatech’s growth. More detailed information about D&D Pharmatech can be found on its official website.

게시물 D&D Pharmatech Partners with LG AI Research Institute to Accelerate Oral Peptide New Drug Development이 솜삽 블로그에 처음 등장했습니다.